Sa'ed Al-Olimat, PharmD: No financial relationships to disclose
Psychedelics are DEA Schedule I controlled substances and are therefore illegal under federal law. The FDA has issued guidance for clinical investigations of psychedelic therapeutics and research is evolving. Attend this presentation for an overview of ketamine, MDMA, and psilocybin as it relates to psychedelic care and to prepare you to answer questions as the field evolves.
Learning Objectives:
Describe psychedelic therapeutics that are currently being studied for pharmacologic effect in various syndromes.
Interpret clinical studies discussing the efficacy of psychedelic therapeutics for treating various syndromes.
Examine available safety evidence for the use of psychedelic therapeutics.
Discuss ethical and legal considerations for psychedelic therapeutics.
